

September 8, 2011:

Christopher S. Bond Life Sciences Center

Columbia, Missouri



Keynote Speaker

Christopher S. Bond

Christopher S. Kit Bond, a former four-term United States Senator from Missouri, is a partner at [Thompson Coburn](#) in the Public Finance and Public Law practice group. Drawing from the knowledge and experience he gained during his nearly 40 years of public service, Bond represents clients on matters related to international trade, economic development, biotechnology, agriculture and transportation. He works from the firm's Washington, D.C. and St. Louis offices.



Senator Bond has focused much of his energy on fostering business growth and economic development. During his time in the U.S. Senate, he became a recognized expert and leader on a wide range of subjects, including international trade and Asia; transportation and economic development; cyberintelligence and national security; and plant biotechnology. He was a senior member of the Senate Appropriations Committee and ranking member and Chairman of the subcommittees that fund our nation's housing and transportation programs, and he served as the Vice Chairman of the Senate Select Intelligence Committee. He recently was awarded the National Intelligence Distinguished Public Service Medal.

Prior to his career in the U.S. Senate, Bond served two terms as Governor of Missouri, from 1973 to 1977 (the youngest in the state's history at age 33) and from 1981 to 1985. Before being elected State Auditor in 1970, he was chief counsel of Missouri's Consumer Protection Division. In addition, he served as a judicial clerk to the Chief Judge of the U.S. Fifth Circuit Court of Appeals in Atlanta after graduating first in his class from the University of Virginia Law School.

Executive Panel

Ronald R. Wood

Mr. Wood presently has a private law practice principally focused on renewable energy project development.

Mr. Wood was continuously associated with Black & Veatch from February 1964 until February 2006 when he retired following forty-two years of service. He was at the time of his retirement President & CEO of the Black & Veatch energy business. Black & Veatch is among the largest global infrastructure companies with operations in 70 countries on six continents providing engineering and construction services for water and energy projects.



As President & CEO of B&V Energy, Black & Veatch Corporation, Mr. Wood was responsible for the overall performance of the consolidated Black & Veatch energy business including engineering, procurement, and construction services for energy industry infrastructure projects. Those projects include coal-fired electric power generation; combustion turbine electric power generation; gas, oil, and chemical projects; air quality control system projects; nuclear-fueled power generation services; electric power delivery projects; and, consulting engineering services. B&V Energy has production offices in the United States, Thailand, China, and India comprising about 3,000 professionals that execute design-build projects in North and South America, Asia, Europe, Africa, and the Middle East.

Mr. Wood served as an executive officer and a member of the Board of Directors of Black & Veatch Holding Company beginning in 1999 until his retirement.

He was associated with the World Energy Council (WEC) for many years and is a past member of the WEC Officers Council and Board of Directors. WEC is a global organization comprising over ninety countries focused on sustainable energy solutions.

Mr. Wood's focus as the Black & Veatch energy business leader was on optimum solutions and improved project execution. He instituted a six-sigma continuous improvement program and was particularly interested in creative energy applications including innovative hybrid thermal and membrane desalination; and, both coal and biomass gasification.

Thomas (Ted) Day


Ted Day grew up in Rolla graduating from Rolla High School in 1979. In 1984 he married his high school sweetheart (Kim) and in 1987 had their only son, (Bret). After graduating from pharmacy school in 1986 from the University of Missouri-Kansas City, he went to Fort Leonard Wood General Hospital where he acted as the Clinical Coordinator for their Pharmacy Department. Ted has been the Director of Pharmacy at both



Salem Memorial District Hospital and Phelps County Regional Hospital from 1990 to 1997 where he was responsible for the coordination of pharmaceutical services and experimental drug research. In 1997 he was promoted to Director of Ancillary Services. In 1998 he joined Mo-Sci Corporation as Executive Vice President. He was promoted to the President of the company in 2005. In 2007 he became the sole owner of Mo-Sci Corporation, a company that manufactures high-tech glass products for health care, automotive and aerospace industries. Founded in 1984 by his father, Delbert Day, Mo-Sci has been internationally recognized for its contributions to innovative product development. Ted's research interests include continued development of new treatments for inoperable cancers using radioactive glass bead technologies and the development of new bone-forming treatments for patients suffering from orthopedic injuries or disease. He has received numerous outstanding pharmacy achievement awards and is a member of Sigma Xi Research Society. He is active in the Rolla community serving on The Phelps County Community Partnership Board, Phelps Regional Health Care Foundation Board, and the Presbyterian Manor of Rolla Board. Ted is also active in The First United Methodist Church Board of Trustees, Kiwanis Club, RREC, Hypoint Tenant's Association, RTC Health Advisory Group and The Community Child Care Development Corporation. His hobbies include flying with his father, reading Tom Clancy novels, and working with his dog (Berkley).

Gregg Scheller

Gregg Scheller is the current CEO of Katalyst Surgical, LLC. Katalyst is a medical device company focused on the development of surgical products for ophthalmology. He was previously the Director of Entrepreneurship and Industry Partnerships and Co-Director of the MU Biodesign and Innovation Program at the University of Missouri-Columbia (MU), College of Engineering. In these positions, he lead strategic technical business development with faculty and students. In 2008-09, his entrepreneurial efforts included serving as Executive Director of Nanotechnology Enterprises, Inc. and Executive Agent and founder of the NanoTechnology Enterprise Consortium. He currently serves on the Board of Directors for MU's Biodesign and Innovation Program.



With a Mechanical Engineering degree from the University of Missouri-Columbia, Mr. Scheller has been Founder/CEO of three consecutive successful medical device companies, taking the second company public in 2005. Mr. Scheller is listed as inventor on over 50 U.S. Patents and was the 2007 Ernst & Young Midwest Life Sciences Entrepreneur of the Year.

Suzanne Magee

Suzanne Magee, a native of St. Louis, Missouri, is co-founder, CEO and President of TechGuard Security, an Information Technology products and services company mission-focused on



US Critical Infrastructure Security and National Cyberdefense. Founded in February 2000, TechGuard is a women-owned, small, disadvantaged business, providing trusted security services, research and development, and training programs to defense and intelligence communities, federal and state governments and commercial clients. TechGuard services include network vulnerability analysis, certification and accreditation of systems, systems testing and evaluation, security architecture development and certified security awareness training programs.

Suzanne contributes volunteer hours to several groups in the Missouri area and has won many honors including the National Association of Women Business Owners (NAWBO) Public Policy Advocate of the Year Award; Distinguished Woman Business Owner; Missouri Regional Top 50 Company; SBA Small Business Team of the Year for the Eastern Missouri Region; St. Louis Economic Council Entrepreneurial Company of the year; and Maryland IT Incubator Company of the Year. TechGuard is located in incubator facilities in the St. Louis Enterprise Center in St. Louis, Missouri, in the UMBC Technology Center in Baltimore, Maryland, and in the Western Michigan Science and Technology Initiative in Grand Rapids, Michigan.

Martin E. Sanders, M.D.

Dr. Sanders received his B.A. in Microbiology, Magna Cum Laude and with General Honors, from the University of Missouri in 1972. His undergraduate honors include being a National Merit Scholar and being elected to Phi Beta Kappa. He received his M.D. degree from the University of Chicago in 1979. From 1979 to 1982 he served as an intern and resident in Internal Medicine at Barnes Hospital, Washington University Medical Center, in St. Louis. He was a Medical Staff Fellow at the National Institute of Allergy and Infectious Diseases and at the National Cancer Institute from 1982 to 1988, and a rheumatology fellow at Johns Hopkins Medical School from 1984 to 1985. Dr. Sanders is certified by the American Board of Internal Medicine, and holds dual sub-specialty board certifications in allergy/clinical immunology, and in rheumatology. While at the NIH, Dr. Sanders was co-discoverer of the LFA-1/ICAM-1 and the CD2/LFA-3 receptor/ligand mechanisms of leukocyte adhesion. These molecular relationships were the first two heterophilic membrane protein intercellular receptor-ligand systems described in biology, and thereby represented a fundamental advance in immunology, and structural and cellular biology. Dr. Sanders also was the discoverer of the first described phenotypic and functional distinctions of human memory and naïve T-cell subsets, including differences in expression of multiple adhesion molecules and CD45 isoforms. His peer-reviewed papers have been directly cited by other publications over 6000 times.

Dr. Sanders held concurrent appointments in drug discovery and clinical pharmacology at the Upjohn Company where he helped develop ATGAM (horse anti-human thymocyte polyclonal antibody) the first immunotherapeutic biologic approved by the FDA, for treatment of transplant rejection and an autoimmune disease (autoimmune aplastic anemia). From 1988 to 1990, and concurrent appointments as Director of Immunobiology Preclinical Research and Director of Clinical Immunology Research at Centocor, Inc., from 1990 to 1992. At Centocor, Dr. Sanders was responsible for design and conduct of many of the earliest controlled clinical trials of recombinant monoclonal antibodies for treatment of various autoimmune diseases; and was the director of the first clinical trials demonstrating effectiveness of TNF inhibition for the treatment of both rheumatoid arthritis, and Crohn's disease.

Since 1992, Dr. Sanders has served as an advisor to more than 50 biopharmaceutical companies, in the areas of preclinical and clinical product development. He has participated in the design, execution, monitoring, or analysis of greater than 250 clinical trials; with more than 50 different drugs, biologics (nine FDA approved biologics, including Remicade, Enbrel, Rituxan, Tysabri, Amevive, and Kineret), gene therapies, and devices, across diverse therapeutic areas, including rheumatology, allergy, immunology, oncology, and metabolic diseases. From 2004 to 2007 Dr. Sanders was a venture partner and partner with Charter Life Sciences, a venture capital fund, and served as President and CEO of Palingen, Inc., one of the fund's portfolio companies, focused on treatment of lymphomas and leukemias. He has served on the boards of nine privately held biopharmaceutical companies. He currently serves as Chairman of three privately held companies: Viator Technologies, Inc. developing diagnostics for circulating tumor cells; Io Therapeutics, Inc., developing novel treatments for prostate cancer and autoimmune diseases; and Tekunex, Inc., developing novel approaches to regenerative medicine for cartilage and bone.

Investor Panel

Jeff Craver

Mr. Craver is a member of Advantage Capital's national expansion team and works to develop and expand capital formation and economic development programs. He sits on the board of directors for the Missouri Biotechnology Association as well as the Missouri Institute of Biotechnology and Innovation. He also serves on the policy councils for the International Economic Development Council, the National Association of Seed and Venture Funds, and both the Missouri and Illinois Chambers of Commerce and Industry. Before joining Advantage Capital in 2006, Mr. Craver was Tax Counsel for the Missouri Chamber of Commerce and Industry.



Mr. Craver's background is focused heavily on tax and economic development law and the legislative process. Prior to joining the Missouri Chamber, he was general counsel for the Missouri Senate's Research Division. He also served as bill drafter for the Senate Committees on Ways and Means, Tax Policy, and Economic Development. Before joining the Senate, Mr. Craver worked for the General Counsel's Office for the Missouri Department of Revenue and was engaged in private corporate law practice in Virginia.

Mr. Craver earned a bachelor's degree in history and French from Duke University. He earned his J.D. degree from the University of Richmond and an LL.M. degree in taxation from Washington University in St. Louis. Mr. Craver also has earned a Maîtrise des Etudes Juridiques Européennes et Internationales from the University of Paris.

Dan Janiak

Dan Janiak is an Associate with DFJ Mercury, where he focuses on developing and originating science-based investment themes and startup opportunities. Prior to DFJ Mercury, Dan was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community. While at In-Q-Tel, Dan was responsible for the management and oversight of technology development programs in numerous In-Q-Tel portfolio companies. In addition, he was responsible for leading technical due diligence on all potential investment candidates in the advanced materials space.



Dan received his BS and PhD in Materials Science and Engineering from the University of Maryland. While at Maryland, Dan was a Future Faculty Fellow and held the Robert E. Fischell Fellowship in Biomedical Engineering, conducting research in the design, synthesis and characterization of artificial antibodies with applications in medical diagnostics and biopharmaceutical purification.

Chris Silva

Chris Silva is CEO of Allied Minds, Inc. Allied Minds is the premier private equity-funded innovation company that commercializes U.S. university inventions on a national scale with nearly 40 university partnerships across the country. Allied Minds forms, funds, manages and builds technology based startup companies. Chris sits on the boards of 14 Allied Minds portfolio companies. Before joining Allied Minds, Chris was a Partner at JSA Partners, a professional M&A and strategy firm in Boston. In addition, he was in A.T. Kearney's Aerospace Aviation and Defense Practice and also was the Director of Business Development for GRC International, a scientific and technical support contractor to the Department of Defense and US Intelligence Community. Earlier, Chris served in the U.S. Air Force and Intelligence Community.



His education includes a degree in economics from Tufts University and a Masters of Business Administration.

Bill Rowe

Bill Rowe is a Principal and the Executive Vice President of TIF Marketing Group. Bill is an accomplished business leader and innovator with a demonstrated track record of growing successful businesses, both inside existing Fortune 500 organizations and as stand-alone companies. Bill has served in a broad range of business development, product

commercialization, alliance management and leadership positions in professional services, healthcare and technology markets. Throughout his career, Bill has leveraged proven skills in effective management, consultative sales, strategic marketing and alliance development, combined with a demonstrated success in leading teams to optimize company growth and profitability through constant innovation.

At The Incubation Factory, Bill's role is to manage the Front-End component of technology identification; including; marketing, sourcing, conducting diligence and licensing of high-potential opportunities.